BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ampuero J, Pais R, Aller R, Gallego-Durán R, Crespo J, García-Monzón C, Boursier J, Vilar E, Petta S, Zheng MH, Escudero D, Calleja JL, Aspichueta P, Diago M, Rosales JM, Caballería J, Gómez-Camarero J, Lo Iacono O, Benlloch S, Albillos A, Turnes J, Banales JM, Ratziu V, Romero-Gómez M; HEPAmet Registry. Development and Validation of Hepamet Fibrosis Scoring System-A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis. Clin Gastroenterol Hepatol 2020;18:216-225.e5. [PMID: 31195161 DOI: 10.1016/j.cgh.2019.05.051] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 18.0] [Reference Citation Analysis]
Number Citing Articles
1 Perdomo CM, Garcia-Fernandez N, Escalada J. Diabetic Kidney Disease, Cardiovascular Disease and Non-Alcoholic Fatty Liver Disease: A New Triumvirate? J Clin Med 2021;10:2040. [PMID: 34068699 DOI: 10.3390/jcm10092040] [Reference Citation Analysis]
2 Alqahtani SA, Schattenberg JM. Nonalcoholic fatty liver disease: use of diagnostic biomarkers and modalities in clinical practice. Expert Rev Mol Diagn 2021;:1-14. [PMID: 34346799 DOI: 10.1080/14737159.2021.1964958] [Reference Citation Analysis]
3 Xin Z, Liu S, Niu J, Xu M, Wang T, Lu J, Chen Y, Wang W, Ning G, Bi Y, Xu Y, Li M, Zhao Z. The association of low-grade albuminuria with incident non-alcoholic fatty liver disease and non-invasive markers of liver fibrosis by glycaemia status. Liver Int 2021;41:101-9. [PMID: 32840963 DOI: 10.1111/liv.14649] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Zambrano-huailla R, Guedes L, Stefano JT, de Souza AAA, Marciano S, Yvamoto E, Michalczuk MT, Vanni DS, Rodriguez H, Carrilho FJ, Alvares-da-silva MR, Gadano A, Arrese M, Miranda AL, Oliveira CP. Diagnostic performance of three non-invasive fibrosis scores (Hepamet, FIB-4, NAFLD fibrosis score) in NAFLD patients from a mixed Latin American population. Annals of Hepatology 2020;19:622-6. [DOI: 10.1016/j.aohep.2020.08.066] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
5 Zhou YJ, Wong VW, Zheng MH. Consensus scoring systems for nonalcoholic fatty liver disease: an unmet clinical need. Hepatobiliary Surg Nutr 2021;10:388-90. [PMID: 34159171 DOI: 10.21037/hbsn-21-80] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Ampuero J, Aller R, Gallego-durán R, Crespo J, Calleja JL, García-monzón C, Gómez-camarero J, Caballería J, Lo Iacono O, Ibañez L, García-samaniego J, Albillos A, Francés R, Fernández-rodríguez C, Diago M, Soriano G, Andrade RJ, Latorre R, Jorquera F, Morillas RM, Escudero D, Estévez P, Guerra MH, Augustín S, Banales JM, Aspichueta P, Benlloch S, Rosales JM, Salmerón J, Turnes J, Romero Gómez M. Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH. Journal of Hepatology 2020;73:17-25. [DOI: 10.1016/j.jhep.2020.02.028] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 14.0] [Reference Citation Analysis]
7 Arab JP, Dirchwolf M, Álvares-da-Silva MR, Barrera F, Benítez C, Castellanos-Fernandez M, Castro-Narro G, Chavez-Tapia N, Chiodi D, Cotrim H, Cusi K, de Oliveira CPMS, Díaz J, Fassio E, Gerona S, Girala M, Hernandez N, Marciano S, Masson W, Méndez-Sánchez N, Leite N, Lozano A, Padilla M, Panduro A, Paraná R, Parise E, Perez M, Poniachik J, Restrepo JC, Ruf A, Silva M, Tagle M, Tapias M, Torres K, Vilar-Gomez E, Costa Gil JE, Gadano A, Arrese M. Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease.Ann Hepatol. 2020;19:674-690. [PMID: 33031970 DOI: 10.1016/j.aohep.2020.09.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
8 Ciardullo S, Ronchetti C, Muraca E, Oltolini A, Perra S, Bianconi E, Zerbini F, Cannistraci R, Manzoni G, Gastaldelli A, Lattuada G, Perseghin G. Impact of using different biomarkers of liver fibrosis on hepatologic referral of individuals with severe obesity and NAFLD. J Endocrinol Invest 2020;43:1019-26. [PMID: 32008185 DOI: 10.1007/s40618-020-01188-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
9 Maya-Miles D, Ampuero J, Gallego-Durán R, Dingianna P, Romero-Gómez M. Management of NAFLD patients with advanced fibrosis. Liver Int 2021;41 Suppl 1:95-104. [PMID: 34155801 DOI: 10.1111/liv.14847] [Reference Citation Analysis]
10 Ampuero J, Aller R, Gallego-Durán R, Crespo J, Abad J, González-Rodríguez Á, Gómez-Camarero J, Caballería J, Lo Iacono O, Ibañez L, García-Samaniego J, Martín-Mateos R, Francés R, Fernández-Rodríguez C, Diago M, Soriano G, Andrade RJ, Latorre R, Jorquera F, Morillas RM, Escudero D, Estévez P, Hernández-Guerra M, Augustín S, Pareja-Megia MJ, Banales JM, Aspichueta P, Benlloch S, Rosales JM, Salmerón J, Turnes J, Romero-Gómez M; HEPAmet Registry. Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects. Liver Int 2021;41:2076-86. [PMID: 33896100 DOI: 10.1111/liv.14898] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Arrese M, Arab JP, Barrera F, Kaufmann B, Valenti L, Feldstein AE. Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity. Semin Liver Dis 2021. [PMID: 34233370 DOI: 10.1055/s-0041-1730927] [Reference Citation Analysis]
12 El-Serag HB, Kanwal F, Feng Z, Marrero JA, Khaderi S, Singal AG; Texas Hepatocellular Carcinoma Consortium. Risk Factors for Cirrhosis in Contemporary Hepatology Practices-Findings From the Texas Hepatocellular Carcinoma Consortium Cohort. Gastroenterology 2020;159:376-7. [PMID: 32234536 DOI: 10.1053/j.gastro.2020.03.049] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
13 Soon G, Wee A. Updates in the quantitative assessment of liver fibrosis for nonalcoholic fatty liver disease: Histological perspective. Clin Mol Hepatol 2021;27:44-57. [PMID: 33207115 DOI: 10.3350/cmh.2020.0181] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
14 Ballestri S, Mantovani A, Baldelli E, Lugari S, Maurantonio M, Nascimbeni F, Marrazzo A, Romagnoli D, Targher G, Lonardo A. Liver Fibrosis Biomarkers Accurately Exclude Advanced Fibrosis and Are Associated with Higher Cardiovascular Risk Scores in Patients with NAFLD or Viral Chronic Liver Disease. Diagnostics (Basel) 2021;11:98. [PMID: 33435415 DOI: 10.3390/diagnostics11010098] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
15 Tanase DM, Gosav EM, Costea CF, Ciocoiu M, Lacatusu CM, Maranduca MA, Ouatu A, Floria M. The Intricate Relationship between Type 2 Diabetes Mellitus (T2DM), Insulin Resistance (IR), and Nonalcoholic Fatty Liver Disease (NAFLD).J Diabetes Res. 2020;2020:3920196. [PMID: 32832560 DOI: 10.1155/2020/3920196] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 12.0] [Reference Citation Analysis]
16 Campos-Murguía A, Ruiz-Margáin A, González-Regueiro JA, Macías-Rodríguez RU. Clinical assessment and management of liver fibrosis in non-alcoholic fatty liver disease. World J Gastroenterol 2020; 26(39): 5919-5943 [PMID: 33132645 DOI: 10.3748/wjg.v26.i39.5919] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
17 Ciardullo S, Monti T, Sala I, Grassi G, Mancia G, Perseghin G. Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in US Adults Across Blood Pressure Categories. Hypertension 2020;76:562-8. [PMID: 32594797 DOI: 10.1161/HYPERTENSIONAHA.120.15220] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
18 Lee CO, Li HL, Tsoi MF, Cheung CL, Cheung BMY. Association between the liver fat score (LFS) and cardiovascular diseases in the national health and nutrition examination survey 1999-2016. Ann Med 2021;53:1065-73. [PMID: 34184611 DOI: 10.1080/07853890.2021.1943514] [Reference Citation Analysis]
19 Marques V, Afonso MB, Bierig N, Duarte-Ramos F, Santos-Laso Á, Jimenez-Agüero R, Eizaguirre E, Bujanda L, Pareja MJ, Luís R, Costa A, Machado MV, Alonso C, Arretxe E, Alustiza JM, Krawczyk M, Lammert F, Tiniakos DG, Flehmig B, Cortez-Pinto H, Banales JM, Castro RE, Normann A, Rodrigues CMP. Adiponectin, Leptin, and IGF-1 Are Useful Diagnostic and Stratification Biomarkers of NAFLD. Front Med (Lausanne) 2021;8:683250. [PMID: 34249975 DOI: 10.3389/fmed.2021.683250] [Reference Citation Analysis]
20 Miyoshi T, Hamaguchi M, Kitagawa N, Hashimoto Y, Fukui M. Correlation between Liver Stiffness by Two-Dimensional Shear Wave Elastography and Waist Circumference in Japanese Local Citizens with Abdominal Obesity. J Clin Med 2021;10:1971. [PMID: 34064337 DOI: 10.3390/jcm10091971] [Reference Citation Analysis]
21 Younes R, Caviglia GP, Govaere O, Rosso C, Armandi A, Sanavia T, Pennisi G, Liguori A, Francione P, Gallego-Durán R, Ampuero J, Garcia Blanco MJ, Aller R, Tiniakos D, Burt A, David E, Vecchio FM, Maggioni M, Cabibi D, Pareja MJ, Zaki MYW, Grieco A, Fracanzani AL, Valenti L, Miele L, Fariselli P, Petta S, Romero-Gomez M, Anstee QM, Bugianesi E. Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease. J Hepatol 2021:S0168-8278(21)00343-3. [PMID: 34090928 DOI: 10.1016/j.jhep.2021.05.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
22 Castellana M, Donghia R, Guerra V, Procino F, Castellana F, Zupo R, Lampignano L, Sardone R, De Pergola G, Romanelli F, Trimboli P, Giannelli G. Fibrosis-4 Index vs Nonalcoholic Fatty Liver Disease Fibrosis Score in Identifying Advanced Fibrosis in Subjects With Nonalcoholic Fatty Liver Disease: A Meta-Analysis. Am J Gastroenterol 2021;116:1833-41. [PMID: 34160377 DOI: 10.14309/ajg.0000000000001337] [Reference Citation Analysis]
23 Cao YX, Zhang M, Zhang HW, Jin JL, Liu HH, Zhang Y, Guo YL, Wu NQ, Zhu CG, Xu RX, Gao Y, Dong Q, Sun J, Li JJ. Impact of liver fibrosis score on prognosis in patients with previous myocardial infarction: A prospective cohort study. Liver Int 2021;41:1294-304. [PMID: 33389804 DOI: 10.1111/liv.14780] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
24 Rios RS, Zheng KI, Targher G, Byrne CD, Zheng MH. Non-invasive fibrosis assessment in non-alcoholic fatty liver disease. Chin Med J (Engl) 2020;133:2743-5. [PMID: 32932282 DOI: 10.1097/CM9.0000000000000989] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Sun DQ, Zheng KI, Xu G, Ma HL, Zhang HY, Pan XY, Zhu PW, Wang XD, Targher G, Byrne CD, Chen YP, Yuan WJ, Zheng MH. PNPLA3 rs738409 is associated with renal glomerular and tubular injury in NAFLD patients with persistently normal ALT levels. Liver Int. 2020;40:107-119. [PMID: 31519069 DOI: 10.1111/liv.14251] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 15.5] [Reference Citation Analysis]
26 Arab JP, Díaz LA, Dirchwolf M, Mark H, Lazarus JV, Vaughan E, Méndez-Sánchez N, de Oliveira CP, Gadano A, Arrese M. NAFLD: Challenges and opportunities to address the public health challenge in Latin America. Ann Hepatol 2021;24:100359. [PMID: 34004366 DOI: 10.1016/j.aohep.2021.100359] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Geier A, Tiniakos D, Denk H, Trauner M. From the origin of NASH to the future of metabolic fatty liver disease. Gut 2021:gutjnl-2020-323202. [PMID: 33632710 DOI: 10.1136/gutjnl-2020-323202] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]